SCHEMBL4496162

SCHEMBL4496162

Nc1ccc(-c2ccc(N3CCCN(C4CC4)CC3)nn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.41
RAB9A P51151 4/20 0.41
MAPT P10636 4/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HRH3 Q9Y5N1 4/20 0.40
SCD O00767 2/20 0.40
AXL P30530 1/20 0.38
HRH4 Q9H3N8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1743326 0.95 NPC1 (0.44) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL4496153 0.84 HRH3 (0.45) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL13648900 0.81 NPC1 (0.56) NPC1RAB9AMAPTMEN1KMT2A
Hydrochloric Acid SCHEMBL3970563 0.80 NPC1 (0.54) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL1742473 0.80 CNR2 (0.44) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL1742397 0.79 NPC1 (0.57) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL3967998 0.79 MAPT (0.51) MAPTMEN1KMT2AALDH1A1HRH3
SCHEMBL1744595 0.79 NPC1 (0.56) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL3043622 0.79 HRH3 (0.48) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL1744279 0.78 NPC1 (0.41) NPC1RAB9AMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846677-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2014-09-30 US disclosed
US-8501739-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-06 US disclosed
US-20120232078-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 US disclosed
US-20090312309-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2009-12-17 US disclosed
EP-1902028-A2 HISTAMINE H3 RECEPTOR ANTAGONISTS Novo Nordisk A/S (DK) 2008-03-26 EP disclosed
WO-2007003604-A2 HISTS1MINE H3 RECEPTOR ANTAGONISTS NOVO NORDISK A/S (DK) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232078-A1 Novel Medicaments HRH3, HRH4, HRH1 NPC1 2646/4885RAB9A 4607/4885MAPT 2828/4885
US-20090312309-A1 Novel Medicaments HRH3, HRH4, HRH1 NPC1 2646/4885RAB9A 4607/4885MAPT 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.